Keck School Faculty

Ann F Mohrbacher, MD
Ann F Mohrbacher, MD
Associate Professor of Clinical Medicine;Medical Director, Autologous Bone Marrow Transplant
Medicine
1441 Eastlake Ave. Health Sciences Campus Los Angeles
Dr. Mohrbacher, a graduate of Harvard Medical School, is a devoted educator, researcher and medical practitioner. She has several hematology related research interests and activities, including bone marrow transplantation, and has received thousands of dollars in research grants. She has been published in a number of medical journals and has been invited to lecture on topics including Radioimmunotherapy of non-Hodgkin’s lymphoma and B-cell targeted therapy of rheumatoid arthritis. Dr. Mohrbacher is a member of the Southern California Lymphoma Group and currently belongs to a number of university related committees, such as the Post-Graduate Education Committee and the Clinical Investigations Committee.

American Society of Clinical Oncology: Career Development Award, 1995

American Society of Clinical Oncology: Ooops. Something went wrong., 1995

Harvard University : A.B. Magna Cum Laude, 1983

Harvard University: Scholarship, 1983

Harvard University : Ooops. Something went wrong., 1983

Harvard University: Ooops. Something went wrong., 1983

Unrelated HLA mismatched microtransplantation in a patient with refractory secondary acute myeloid leukemia Leuk Res Rep. 2018; 9:18-20. . View in PubMed

Asian-variant intravascular large B-cell lymphoma Proc (Bayl Univ Med Cent). 2017 Apr; 30(2):186-189. . View in PubMed

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618. . View in PubMed

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM Blood. 2016 06 09; 127(23):2833-40. . View in PubMed

An effective reinduction regimen for first relapse of adult acute lymphoblastic leukemia Med Oncol. 2013 Dec; 30(4):744. . View in PubMed

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma Blood. 2012 Jul 19; 120(3):552-9. . View in PubMed

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma J Clin Oncol. 2012 Jun 01; 30(16):1960-5. . View in PubMed

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial Br J Haematol. 2011 Aug; 154(4):533-5. . View in PubMed

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma Cancer Chemother Pharmacol. 2011 Jan; 67(1):57-67. . View in PubMed

A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation Epigenetics. 2010 Nov-Dec; 5(8):750-7. . View in PubMed

Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus J Clin Pathol. 2007 May; 60(5):562-4. . View in PubMed

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial Cancer. 2006 Feb 15; 106(4):848-58. . View in PubMed

B cell non-Hodgkin's lymphoma: rituximab safety experience Arthritis Res Ther. 2005; 7 Suppl 3:S19-25. . View in PubMed

Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myelomaA phase II International Oncology Study Group study. Cancer. 2002 May 15; 94(10):2645-52. . View in PubMed

Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications Blood. 2000 May 01; 95(9):2990-2. . View in PubMed

The influence of patient-related factors on ex vivo retroviral-mediated gene transfer into mobilized peripheral blood myeloid progenitors Hum Gene Ther. 1998 May 01; 9(7):1061-8. . View in PubMed

Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion Blood. 1993 Dec 15; 82(12):3712-20. . View in PubMed

Powered by SC CTSI
Go to Top